What is HC Wainwright’s Estimate for MDGL Q1 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Thursday, February 27th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will post earnings of ($2.83) per share for the quarter, down from their prior estimate of ($2.10). HC Wainwright has a “Buy” rating and a $405.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q2 2025 earnings at ($2.14) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($7.82) EPS, FY2026 earnings at $9.85 EPS, FY2027 earnings at $31.36 EPS, FY2028 earnings at $52.07 EPS and FY2029 earnings at $87.27 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, beating analysts’ consensus estimates of ($4.32) by $1.61. The company had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million.

A number of other research analysts have also recently issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. Citigroup upped their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a report on Thursday, February 27th. B. Riley raised shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and upped their target price for the stock from $236.00 to $422.00 in a research note on Thursday, February 27th. Finally, JMP Securities reissued a “market outperform” rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $375.75.

Madrigal Pharmaceuticals Stock Down 8.1 %

Shares of NASDAQ MDGL opened at $313.47 on Monday. Madrigal Pharmaceuticals has a 52-week low of $189.00 and a 52-week high of $377.46. The stock has a market cap of $6.84 billion, a P/E ratio of -12.50 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The firm has a 50 day moving average price of $322.98 and a 200 day moving average price of $285.80.

Insiders Place Their Bets

In other news, VP Robert E. Waltermire sold 442 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $120,847.22. Following the transaction, the vice president now directly owns 5,058 shares of the company’s stock, valued at $1,382,907.78. This represents a 8.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Rebecca Taub sold 1,689 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $461,789.49. Following the sale, the chief marketing officer now directly owns 457,310 shares of the company’s stock, valued at $125,033,127.10. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,560 shares of company stock valued at $6,932,536 over the last 90 days. 22.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Several hedge funds have recently bought and sold shares of MDGL. Oppenheimer Asset Management Inc. increased its stake in shares of Madrigal Pharmaceuticals by 2.1% during the third quarter. Oppenheimer Asset Management Inc. now owns 1,507 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 31 shares during the period. Pitcairn Co. lifted its holdings in shares of Madrigal Pharmaceuticals by 3.2% during the fourth quarter. Pitcairn Co. now owns 1,060 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 33 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Madrigal Pharmaceuticals by 1.8% in the third quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company’s stock valued at $486,000 after acquiring an additional 40 shares during the period. Sanctuary Advisors LLC grew its position in shares of Madrigal Pharmaceuticals by 5.2% during the 4th quarter. Sanctuary Advisors LLC now owns 1,247 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 62 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Madrigal Pharmaceuticals by 47.6% during the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 68 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.